Genomic Health, Inc. (Nasdaq: GHDX) recently announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score™ is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001).
Oncotype DX DCIS Score Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer
Halozyme Announces Presentations of Preclinical Data at the San Antonio Breast Cancer Symposium Annual Meeting
Halozyme Therapeutics, Inc.(NASDAQ: HALO) recently announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS). The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
KineMed Biomarker Studies in Chronic Lymphocytic Leukemia Reveal Groundbreaking Approach for Guiding Patient Management and Drug Development
KineMed, Inc. recently announced that two Chronic Lymphocytic Leukemia (CLL) studies utilizing KineMed’s proprietary kinetic biomarker technology, will be presented at the American Society of Hematology Annual Meeting taking place this weekend in San Francisco, California. KineMed’s CLL research collaborators, Jan A. Burger, MD, Ph.D., of the MD Anderson Cancer Center, and Elizabeth J. Murphy, MD, DPhil, from the at the University of California San Francisco Department of Medicine and representing the CLL Research Consortium investigators, will present the studies at the conference.
Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, “pre-malignant” state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer. Findings from both teams appear in the New England Journal of Medicine.
Study Published in Nature Suggests immunoSEQ Assay May Be Used to Predict Response to anti-PD-1 Therapy for Melanoma
Adaptive Biotechnologies, a pioneer in leveraging Next Generation Sequencing (NGS) to profile T- and B-cell receptors, recently reported that the immunoSEQ Assay was able to help identify patients with metastatic melanoma who would be most likely to respond to treatment with pembrolizumab (an anti-PD-1 therapy), according to a study published in Nature.